Mandate

Vinge advises IBT on share issues

November 24, 2017

Vinge advises Infant Bacterial Therapeutics AB (publ) (Nasdaq First North Premier) in connection with a combined directed issue and rights offering of approximately SEK 545 million.

The Vinge team includes Erik Sjöman, Christian Lindhé, Kristoffer Franzkeit, Ludvig Frithiof and Astrid Karlsson.

Related

Vinge advises Summit Partners on its $1 billion-plus investment in Keyfactor

Vinge has, together with Kirkland & Ellis, advised Summit Partners in connection with a strategic growth investment in Keyfactor, a leader in trust infrastructure. The investment will help accelerate the company's global scale and growth initiatives, enabling product innovation, geographic expansion, team building and strategic acquisitions.
July 20, 2026

Vinge has advised VAROPreem in connection with its acquisition of Sunpine

Vinge has advised VAROPreem in connection with its acquisition of Sunpine from Sveaskog, Södra Skogsägarna and Lawter.
July 10, 2026